TNFRSF17 and plasma cell myeloma: A combined treatment of myeloma cells with ATRA and the γ-secretase inhibitor crenigacestat (Figure 1) could further increase BCMA expression, inducing even stronger antigen-specific targeting by BCMA-specific CAR-T cells [24].